SAN JOSE, Calif. – Outset Medical has raised $76.5 million in Series C equity funding. Outset’s technology, the Tablo Hemodialysis System can be used across a range of clinical settings from dialysis clinics to hospitals and skilled nursing facilities. The company will use proceeds from the financing to expand the commercial introduction of the Tablo System in acute and chronic care markets in the United States. Using sensor-based automation, wireless data transmission and a touchscreen interface, Tablo was created to feel and function more like a consumer product than a medical device, said Leslie Trigg, CEO of Outset Medical, in a statement. In the dialysis clinic setting, Tablo’s simplicity and small size allows for a new “self-serve” dialysis model in which patients can set up and monitor their own treatment independently without relying on clinic staff. The self-serve option empowers patients to take more control and ownership of their treatment, and can help create cost efficiencies for dialysis providers. The system connects directly to regular tap water, purifies it on demand and generates streaming dialysis fluid in real-time, while the patient is dialyzing. Because centralized water processing equipment is not required, Tablo expands the settings in which dialysis can be efficiently delivered, and can reduce costs in settings such as hospitals and extended care facilities. “This funding will provide the resources needed to scale our launch and brings us a step closer to making a significant and lasting impact on dialysis care,” said Trigg.
You are here: / / Outset Medical raises $76M for mobile dialysis